Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
Status:
Completed
Trial end date:
2020-12-29
Target enrollment:
Participant gender:
Summary
This will be a phase 1a randomized, open label, multi-center study with approximately 24
subjects. All subjects will receive standard of care (SOC) per institutional guidelines for
treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar
group will receive 5 daily doses of brequinar 100 mg.